The present study explored the expression of coiled-coil domain-containing 34 (CCDC34) in cervical cancer (CC) and its prognostic value.
Background
Cervical cancer (CC) is the second leading cause of death among women worldwide [1] . Although there has been notable progress in CC treatment, including surgical techniques, chemotherapy, and radiotherapy, in the past 2 decades, there are still some early cases that have invasion and metastasis, which directly affects the prognosis of CC [2] . At present, the underlying molecular mechanism of CC pathogenesis is still unclear. Thus, to improve the survival of CC patients, it is important to find new potential prognostic biomarkers and therapeutic targets.
The coiled-coil domain-containing 34 (CCDC34), also named NY-REN-41, includes 373 amino acids and locates in 11p14.1 chromosome. CCDC34 was initially found in a patient with hamartoma of the retinal pigment epithelium and retina [3] . Recently, Gong et al. [4] found that CCDC34 was overexpressed in bladder cancer and promoted its cell proliferation and migration. However, the expression level and prognostic value of CCDC34 in human cervical cancer remain largely unclear.
In this study, GEPIA and Oncomine cancer databases were mined to predict the CCDC34 differential expression level between a CC group and a normal group. Then, immunohistochemical staining was performed to detect the expression levels of CCDC34, VEGF, and microvessel density (MVD) in CC. Moreover, CCDC34 expression level in CC and its correlations with patients' clinicopathological characteristics and survival prognosis were investigated.
Material and Methods
Bioinformatics mining GEPIA (http://gepia.cancer-pku.cn/) and Oncomine (https:// www.oncomine.org/resource/login.html) cancer databases were mined to predict the CCDC34 differential expression level between a CC group and a normal group.
Patients and corresponding clinical characteristics
We retrospectively included 67 patients diagnosed with cervical cancer after radical surgery in our hospital from August 2009 to December 2011. Surgical staging was based on the FIGO system. All patients' clinicopathological factors are listed in Table 1 . This study was approved by the Ethics Committee of the Tumor Hospital of Ganzhou Review Board (No. 20140702). Informed consent was signed by each patient.
Immunohistochemistry and results evaluation
Immunohistochemistry was performed to examine the expression levels of CCDC34 (ab122396, Abcam, Inc.), VEGF (ab2349, Abcam, Inc.) and CD31 (ab28364, Abcam, Inc.) according to the manufacturer's instructions. The working concentration of each antibody was at a dilution of 1: 100. Immunohistochemical scores were calculated based on a previously reported method [5] : "+" score for ³10% of tumor cells positive; "−" score when less than 10% of tumor cells or no visible staining was detected.
MVD counts
MVD counts were calculated by vascular endothelial cells with CD31-positive staining. We used low-magnification (×40) microscopy to identify regions with the maximum number of CD31-positive-staining microvessels. Then, we used high magnification (×100) to count the number of microvessels. Each section was independently observed and calculated by 2 pathologists.
Statistical analysis
SPSS 20.0 software was used to perform the statistical analysis. Data in GEPIA and Oncomine databases were analyzed by the independent-samples t test to compare the differential expression levels of CCDC34 mRNA between the cervical cancer group and the normal group. Pearson c 2 test or Fisher test was employed to evaluate the correlation between CCDC34 expression and clinicopathological factors. Kaplan-Meier univariate and Cox multivariate survival analyses were performed to assess the CCDC34 prognostic value in CC patients. A P value less than 0.05 was considered as a significantly statistical difference.
Results
High expression of CCDC34 and its relationship with CC patients' clinicopathological factors Both GEPIA and Oncomine cancer databases mining results revealed that CCDC34 was more highly expressed in the CC group than that in the normal group (all P<0.05, Figure 1 ). Then, immunohistochemistry was used in 67 cervical cancer and corresponding adjacent tissues to examine the clinicopathological and prognostic significance of CCDC34 in cervical cancer. The positive staining of CCDC34 was primarily located in the cytoplasm and membrane ( Figure 2A Figure 2B ). A statistically significant difference was found between these 2 groups of tissues in the positive rate of CCDC34 (P<0.001, Figure 3) . The relationship between CCDC34 expression levels and CC patients' clinicopathological parameters are listed in Table 1 . High expression of CCDC34 was significantly associated with histological grade (P=0.022), lymph node metastasis (P=0.044), and FIGO stage (P=0.002).
Correlation between CCDC34 and VEGF expression in CC patients
VEGF-positive staining was mainly located in the cytoplasm ( Figure 2C ) and the VEGF-positive staining rate was 59.7% (40/67). The CCDC34-positive and VEGF-positive rate were both 55.2% (37/67), and the consistency of both CCDC34 and VEGF expression was 74.6% (50/67). Furthermore, Spearman's test revealed a strong relationship between CCDC34 and VEGF expression in CC tissues (r=0.563, P=0.000; Table 2 ). Association between CCDC34 and MVD in CC As shown in Figure 4 , CC patients with CCDC34-positive expression had much more MVD than those with CCDC34-negative expression (P=0.000).
Correlation between CCDC34 and CC patients' prognosis
Based on TCGA database, patients with high expression of CCDC34 had worse OS than those with low expression of CCDC34 (P=0.015, Figure 5A ). Compared to those with CCDC34-negative expression, CC patients with CCDC34-positive expression had shorter OS and DFS times (P=0.004, Figure 5B and P=0.005, Figure 5C , respectively).
CCDC34 can serve as a predictive parameter for the prognosis of CC patients
Kaplan-Meier univariate survival analysis showed that CCDC34 expression, recurrence, and FIGO stage had significant prognostic influence on OS and DFS (Table 3) . Cox multivariate survival analysis revealed that CCDC34 was an independent prognostic factor for OS (P=0.039) and DFS (P=0.040) ( Table 4 ).
Discussion
The coiled-coil domain-containing (CCDC) proteins exhibit diverse functions related to their highly versatile folding motif [6] . Previous studies have shown genetic or epigenetic alterations in several CCDC genes in human cancers, including CCDC34 in bladder cancer [4] , colorectal cancer [7] , pancreatic adenocarcinoma [8] , and esophageal squamous cell carcinoma [9] . However, to date, there has been no study focusing on the relationship between CCDC34 and cervical cancer. In this study, our results proved that CCDC34 was overexpressed in cervical cancer compared to corresponding adjacent normal tissues. Further findings demonstrated that high expression of CCDC34 was significantly associated with histological grade, lymph node metastasis, and FIGO stage. These data suggest a key role of CCDC34 in progression and development of cervical cancer.
Accumulating evidence demonstrates that high expression of VEGF is closely related to aggressive behavior and worse prognosis of cancer [10] . In addition, high VEGF expression levels and MVD are strongly associated with unfavorable prognosis of CC patients [11] [12] [13] [14] . In the present study, we similarly observed a significant positive correlation between CCDC34 and VEGF expression in CC tissues. Compared to those with CCDC34-negative expression, patients with CCDC34-positive expression had much more MVD. These findings suggest that CCDC34 participates in tumor angiogenesis of CC, possibly in coordination with VEGF. Similarly, Gong et al. [4] demonstrated that knockdown of CCDC34 retards bladder cancer proliferation and migration by downregulating the PI3K/AKT pathway. The AKT pathway has a pivotal regulatory role in multiple cellular survival pathways, primarily in tumorigenesis and angiogenesis, by regulating VEGF expression [15] . This suggests that CCDC34 facilitates VEGF expression by regulating the PI3K/AKT signaling pathway. Hu et al. [9] found that CCDC34 was highly expressed in ESCC, and high expression of CCDC34 was associated with poor prognosis of ESCC patients, the potential mechanism of which is closely related to the angiogenesis of ESCC; these results are consistent with our own. More in-depth studies are required to elucidate the role of CCDC34 in CC angiogenesis.
We also explored the relationship between CCDC34 expression and prognosis of CC patients. Kaplan-Meier univariate survival analysis demonstrated that patients with CCDC34-positive Table 2 . Correlation between CCDC34 and VEGF expression (cases). 8387 expression had shorter OS and DFS than those with CCDC34-negative expression. In addition, Cox multivariate survival analysis revealed that CCDC34 was an independent unfavorable predictor for OS and DFS of CC patients. The bioinformatics mining results were consistent with our experimental data.
The present study has certain limitations. First, small cervical cancer tissue samples were collected retrospectively, which might to some extent lead to biased statistical results. Second, only immunohistochemical staining, a semi-quantitative method, was used in our validation experiment, and some other quantitative methods like Western blot or qRT-PCR analysis are needed. Third, the exact biological function of CCDC34 in cervical cancer and its detailed molecular regulation mechanisms
were not assessed in this study. We plan to address these deficiencies in our future experiments.
Conclusions
Our results proved that high expression of CCDC34 was closely associated with CC angiogenesis and is as an independent poor prognostic parameter in CC.
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